Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$93.26
$0.37(1.44%)
At close: 4:00 PM EST
$93.26
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$16.64 - $96.50
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$4.76B
Enterprise Value$3.16B
Total Cash (Recent Filing)$404.30M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 07, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding54,448,772
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue1.55K
Enterprise Value/Gross Profit1.55K
Enterprise Value/Ebitda-18.20
Forecast
1Y Price Target
$125.15Price Target Upside34.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.3
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Clinical Trial TimingAcceleration of trial readouts and focusing on a single dosing arm could shorten enrollment and bring pivotal results and potential commercial launch closer, increasing program visibility.
Efficacy And Safety SignalsInterim responder results in the CIDP pivotal trial and supporting MaGic trial data showed strong responder rates and a favorable safety profile, suggesting competitive efficacy potential versus established therapies.
Regulatory FacilitationFDA removal of antinuclear antibody screening and routine testing should reduce enrollment barriers and indicates antibody changes are not viewed as a meaningful safety concern, easing trial conduct.
Bears Say
Financing And Potential DilutionFinancial modeling that includes planned research payments anticipates an additional equity offering because current cash is projected to support operations only into later years, creating potential shareholder dilution.
Limited Data And Program UncertaintyInterim data come from a small patient group and safety for the DNTH212 program remains uncertain, which limits confidence until larger and dedicated safety data are available.
Rising Operating ExpensesHigher projected operating expenses to support multiple simultaneous late stage programs could increase cash burn and strain financial resources, raising the likelihood of external funding needs.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $16.64 and its highest was $96.50 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $4.76B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 8 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Mar 09, 2026. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.006 by -$0.424.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 54,448,772 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.006. Following the earnings report the stock price went up 21.518%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$125.15 (34.20% Upside)
$125.15 (34.20% Upside)
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
0.00%
Trailing 12-Months
Asset Growth
42.00%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$125.15
▲(34.20% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.12% Insiders
19.63% Mutual Funds
0.22% Other Institutional Investors
70.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---